[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Sun Yat-Sen University Cancer Center\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":190},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,41,69,90,110,138,164],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100417997","phase-3-standard-chemotherapy-plus-moxifloxacin-as-first-line-treatment-for-metastatic-triple-negative-breast-cancer-100417997",false,"NCT04722978","Standard Chemotherapy Plus Moxifloxacin as First-line Treatment for Metastatic Triple-negative Breast Cancer","Standard Chemotherapy Plus Moxifloxacin as First-line Treatment for Metastatic Triple-negative Breast Cancer : a Multicenter, Double-blind, Placebo-controlled, Phase 3 Trial","Inclusion Criteria:\n\n* Eastern Cooperative Oncology Group (ECOG) score of 0 to 1.\n* Histologically confirmed invasive ductal carcinoma, no specific type (NOS)\n* ER negative and progesterone receptor (PR) negative (defined as \\\u003C 1% positive cells by IHC), human epidermal growth factor receptor 2 (HER2) negative (defined as IHC 0-1 staining or fluorescent in situ hybridization (FISH) negative).\n* No prior therapy after first recurrence or diagnosis of metastatic disease.\n* At least 1 measurable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST) criteria.\n* Neutrophil-to-lymphocyte ratios (NLR) in peripheral blood ≥ 2.\n* Adequate organ function including bone marrow, renal function, hepatic function, and cardiac reserve (Left ventricular ejection fraction (LVEF) by echocardiogram ≥45%).\n* Compliance with the study protocol.\n* Have provided written and signed informed consent.\n\nExclusion Criteria:\n\n* Pregnant or breast feeding.\n* Definitive breast cancer susceptibility gene (BRCA) mutation, Programmed Cell Death-Ligand 1 (PD-L1) positive, microsatellite instability-high (MSI-H), and mismatch repair deficient (dMMR).\n* Patients who are receiving or will receive other biological agents or immunotherapy.\n* Uncontrolled medical problems.\n* Evidence of active acute or chronic infection.\n* Hepatic, renal, cardiac, or bone marrow dysfunction as detailed above.\n* Concurrent malignancy or history of other malignancy within the last five years.\n* Known severe hypersensitivity to moxifloxacin\n* Patients were unable or unwilling to comply with program requirements.","FEMALE","18 Years","70 Years",{"count":20,"type":21},228,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","The primary objective of this study is to compare progression-free survival (PFS) of patients with metastatic triple-negative breast cancer randomised to treatment with standard chemotherapy plus moxifloxacin or placebo.",[27],"Triple Negative Breast Cancer","RECRUITING","2025-12-10",{"date":31,"type":32},"2025-12-17","ACTUAL",{"date":34,"type":32},"2021-04-20",{"date":36,"type":21},"2026-07",{"name":38,"class":39},"Sun Yat-Sen University Cancer Center","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":48,"minAge":17,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":55,"conditions":56,"keywords":58,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":4},"100615146","phase-1-mitoxantrone-hydrochloride-liposome-and-enlonstobart-combination-treatment-in-patients-with-relapsed-or-refractory-peripheral-t-cell-lymphoma-ptcl-100615146","NCT07288814","Mitoxantrone Hydrochloride Liposome and Enlonstobart Combination Treatment in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma (PTCL)","A Single-Arm, Open-Label Ib\u002FII Study of Mitoxantrone Hydrochloride Liposome and Enlonstobart Combination Treatment in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma（PTCL）","Inclusion Criteria:\n\n1. Centrally confirmed histopathological\u002Fcytologic diagnosis of PTCL with the following subtypes:\n\n   1. Peripheral T-cell lymphoma, not otherwise specified (PTCL, NOS);\n   2. Systemic anaplastic large cell lymphoma (ALK+ and ALK-);\n   3. Follicular helper T (TFH) cell lymphoma of lymph nodes, including angioimmunoblastic, follicular, NOS;\n   4. and any other PTCL subtypes deemed by the investigator to be eligible for inclusion.\n2. Voluntary participation in clinical study; Fully understand and informed the study and sign the written informed consent;\n3. Age ≥18 years old, and ≤ 75 years old, regardless of gender;\n4. Met the criteria of relapsed\u002Frefractory lymphoma: Relapsed lymphoma was defined as relapsed lymphoma more than 6 months after achieving complete remission (CR) after initial chemotherapy. Refractory lymphoma was defined as any of the following criteria: 1) tumor shrinkage \\\u003C 50% or disease progression after at least 4 courses of standard chemotherapy; 2) achieved CR with standard chemotherapy, but relapsed within half a year;\n5. ECOG performance status score: 0-2;\n6. Expected survival time ≥3 months;\n7. There must be at least one measurable or evaluable lesion that meets the Lugano 2014 criteria for lymphoma:\n\n1)Measurable lesion: Nodal lesions with major diameter greater than 1.5cm and minor diameter greater than 1.0cm as assessed by PET\u002FCT or Computed Tomography (CT) and\u002For Magnetic Resonance Imaging (MRI); Or the length of extranodal lesions \\>1.0cm; 2)Evaluable lesions: PET-CT showed increased uptake in lymph nodes or extranodal regions (higher than liver) and imaging features consistent with lymphoma; 8.Have adequate organ and bone marrow function, defined as follows:\n\n1. Blood routine: absolute neutrophil count (ANC) ≥ 1.5×109\u002FL(≥1.0×109\u002FL in patients with bone marrow involvement); platelet count (PLT) ≥ 75×109\u002FL(≥50×109\u002FL in patients with bone marrow involvement), hemoglobin (HGB) ≥ 8.0 g\u002FdL; The patients had not received granulocyte growth factor, platelet transfusion, or red blood cell transfusion within 14 days before the examination;\n2. Liver function: serum total bilirubin (TBIL) ≤1.5× upper limit of normal value (ULN, liver invasion ≤3.0×ULN); alanine aminotransferase (ALT) and aspartate transferase (AST) ≤2.5×ULN (liver invasion ≤5.0×ULN);\n3. Renal function: serum creatinine (Cr) ≤1.5×ULN.\n4. Coagulation function: International Normalized Ratio (INR) ≤1.5 × ULN; Prothrombin Time (PT), Activated PartialThromboplastin Time (APTT) ≤1.5×ULN (unless the subject is receiving anticoagulant therapy, And PT and APTT at screening were within the expected range for anticoagulant therapy).\n5. Thyroid stimulating hormone (TSH) or free thyroxine (FT4) or free triiodothyronine (FT3) within the normal range ±10% (Note: non-autoimmune causes of abnormal TSH, FT3 and FT4 can be maintained in the normal range after replacement treatment of hypothyroidism can be enrolled).\n\n   9.Patients who had received previous antineoplastic therapy could not be enrolled until the toxicity of previous treatment returned to the Common Terminology Criteria for Adverse Events (CTCAE) v5.0 grade score ≤1 or the baseline level; 10.Women of childbearing potential must have a negative serum pregnancy test within 7 days before the first dose of medication; Effective contraception should be used from the time of informed consent until 6 months after the last dose of study drug.\n\nExclusion Criteria:\n\n1. Patients with hemophagocytic lymphohistiocytosis;\n2. Patients with active infection or with obvious B symptoms and high fever should be excluded according to the comprehensive judgment of the investigators;\n3. The subject's previous history of antineoplastic therapy meets one of the following conditions:\n\n   1. Failure to achieve CR or PR after previous treatment with mitoxantrone or mitoxantrone liposome, or relapse within 6 months after treatment;\n   2. Prior treatment with anthracyclines or anthraquinones and cumulative dose of doxorubicin \\> 550 mg\u002Fm2 (liposomal doxorubicin \\> 2000 mg\u002Fm2, epirubicin \\> 1000 mg\u002Fm2, pirarubicin \\> 1000 mg\u002Fm2, mitoxantrone \\> 160 mg\u002Fm2);\n   3. Received anti-tumor treatment (including chemotherapy, targeted therapy, traditional Chinese medicine with anti-tumor activity, etc.) or participated in other clinical trials and received clinical trial drugs within 4 weeks or 5 half-lives (whichever came first) before the first use of the study drug;\n   4. patients who received autologous hematopoietic stem-cell transplantation or allogeneic hematopoietic stem-cell transplantation within 100 days of the first dose of treatment;\n4. Hypersensitivity reaction to any study drug or its components;\n5. Patients with known allergy to any component of the monoclonal antibody;\n6. Patients with a known history of Human Immunodeficiency Virus (HIV) infection and\u002For acquired immunodeficiency syndrome;\n7. Patients with active chronic hepatitis B or active hepatitis C. Hepatitis B SurfaceAntigen (HBsAg) or hepatitis B core Antibody (HBcAb) or Hepatitis C Virus (HCV) during the screening period HCV) antibody positive patients must be further tested for Hepatitis B Virus (HBV) DNA (no more than 1000 copies \u002FmL or 500 IU\u002FmL) and HCV RNA (no more than the lower limit of detection of the assay), Enrollment in the trial occurred after the exclusion of patients with active hepatitis B or hepatitis C infection requiring treatment. Hepatitis B virus (HBV) carriers, medically stable hepatitis B (DNA \\> 1000 copies \u002FmL or 500IU\u002FmL) and cured hepatitis C patients are eligible for enrollment.\n8. Cardiac function and disease is one of the following:\n\n   1. long QTc syndrome or QTc interval \\>480 ms;\n   2. complete left bundle branch block, degree II or III atrioventricular block;\n   3. severe, uncontrolled arrhythmia requiring medical treatment;\n   4. New York College of Cardiology grade ≥ III;\n   5. cardiac ejection fraction (LVEF) less than 50%;\n   6. a history of myocardial infarction, unstable angina, major unstable ventricular arrhythmia or any other arrhythmia requiring treatment, a history of clinically significant pericardial disease, or electrocardiographic evidence of acute ischemic or active conduction system abnormalities within 6 months before recruitment;\n9. Receive live attenuated vaccine (except influenza vaccine) within 4 weeks before enrollment or during the study period;\n10. Previous or current concurrent cancer (except for effectively controlled non-melanoma basal cell carcinoma of the skin, breast\u002Fcervical carcinoma in situ, and other malignancies that have been effectively controlled without treatment within the previous five years);\n11. Those with central nervous system involvement;\n12. Lactating women;\n13. Subjects receiving systemic glucocorticoid therapy or other immunosuppressive therapy for a condition within 14 days before starting study treatment (topical, ocular, intra-articular, nasal, and inhaled glucocorticoids were allowed (minimal systemic absorption); Short-term (≤ 7 days) use of glucocorticoids was permitted for preventive treatment (e.g., contrast allergy) or for the treatment of nonautoimmune conditions (e.g., delayed hypersensitivity from contact allergens).\n14. Had undergone major surgery within 28 days before starting study treatment, or had undergone radiation therapy within the previous 90 days.","ALL","75 Years",{"count":51,"type":21},43,[53,54],"PHASE1","PHASE2","To evaluate the safety of mitoxantrone hydrochloride liposome combined with enlonstobart in the treatment of relapsed or refractory peripheral T-cell lymphoma, to determine the optimal dosage of mitoxantrone hydrochloride liposome within the combination regimen, and to assess the efficacy of the combined therapy.",[57],"Relapsed or Refractory Peripheral T Cell Lymphoma",[59,60],"Mitoxantrone Hydrochloride Liposome","Enlonstobart","NOT_YET_RECRUITING","2025-12-04",{"date":31,"type":32},{"date":65,"type":21},"2025-12-08",{"date":67,"type":21},"2027-12-31",{"name":38,"class":39},{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":48,"minAge":17,"maxAge":4,"enrollmentInfo":76,"targetDuration":4,"studyType":22,"phases":78,"briefSummary":79,"conditions":80,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":40},"100597433","phase-3-fsrt-combines-with-bevacizumab-for-multiple-brain-metastases-in-lung-adenocarcinoma-100597433","NCT07058428","FSRT Combines With Bevacizumab for Multiple Brain Metastases in Lung Adenocarcinoma","Fractionated Stereotactic Radiotherapy Combines With Bevacizumab for the Treatment of Multiple Brain Metastases in Lung Adenocarcinoma: a Prospective Controlled Phase III Study","Inclusion Criteria:\n\n* Age ≥ 18 years old;\n* Cellular or histopathological confirmation of lung adenocarcinoma;\n* Prior to enrollment, brain enhanced magnetic resonance imaging shows (1) 1-2 brain metastases, with at least one measuring ≥3 cm in diameter; or (2) 3-10 brain metastases, with at least one measuring ≥2 cm in diameter; or (3) 11-20 brain metastases; and deemed unsuitable for single-session SRS by radiation oncologists;\n* At the time of enrollment, the extracranial disease status is stable;\n* Eastern Cooperative Oncology Group (ECOG) physical fitness status score 0-2 points\n* Normal liver, kidney, and bone marrow function within 14 days prior to enrollment: peripheral blood white blood cell count ≥ 4 × 10\\^9\u002FL; neutrophil count ≥ 1.5 × 10\\^9\u002FL, platelet count ≥ 100 × 10\\^9\u002FL, hemoglobin ≥ 100g\u002FL, serum creatinine\\\u003C1.5 times the upper limit of normal values; Bilirubin\\\u003C1.5 times the upper limit of normal value; Transaminase\\\u003C2 times the upper limit of normal value;\n* The patient and their family agree and sign an informed consent form.\n\nExclusion Criteria:\n\n* There are contraindications for bevacizumab, such as a history of cardiac and\u002For thromboembolic events, or uncontrolled hypertension;\n* Meningeal metastasis or extensive intracranial metastasis are not suitable for FSRT;\n* Bleeding tendency or coagulation dysfunction;\n* Patients with hemoptysis (≥ 1\u002F2 teaspoon of fresh blood per day) within the past month;\n* Use full dose anticoagulant therapy within the past month;\n* Has experienced severe vascular disease in the past 6 months;\n* Have experienced gastrointestinal fistula, perforation, or abdominal abscess within the past 6 months;\n* Has experienced hypertensive crisis, hypertensive encephalopathy, symptomatic heart failure (New York Class II or above), acute myocardial infarction, cerebral infarction, cerebral parenchymal hemorrhage, or other active cerebrovascular or cardiovascular diseases within the past 6 months;\n* Patients with a history of arterial aneurysm or arteriovenous malformation;\n* Having undergone major surgery within 28 days, or minor surgery or needle biopsy within 48 hours;\n* Urinary protein 3-4+, or 24-hour urinary protein quantification\\>1g;\n* Simultaneously accompanied by serious and uncontrolled other diseases.",{"count":77,"type":21},258,[24],"For non-small cell lung cancer brain metastases, stereotactic radiotherapy is gradually replacing whole brain radiotherapy as the standard treatment. When patients have multiple brain metastases or larger tumors (diameter\\>2cm), single session stereotactic radiotherapy (SRS) may cause significant neurological damage, so fractionated stereotactic radiotherapy (FSRT) is often used. The recent objective remission rate of FSRT is about 50%, and the 1-year intracranial control rate is about 45%, but intracranial progression remains the main factor affecting long-term survival of patients.\n\nBevacizumab is a recombinant humanized monoclonal antibody against vascular endothelial growth factor, which can improve the efficacy of cranial radiotherapy by normalizing neovascularization and improving the hypoxic state of tumor cells. In addition, bevacizumab can improve the abnormal permeability of neovascularization, reduce exudation and extracellular brain edema, thereby further alleviating the toxic side effects associated with brain radiotherapy.\n\nBased on this, this prospective, controlled phase III study will explore the efficacy and safety of the combined use of fractionated stereotactic radiotherapy and bevacizumab in multiple brain metastases of lung adenocarcinoma.",[81],"Multiple Brain Metastases in Lung Adenocarcinoma","2025-11-24",{"date":84,"type":32},"2025-12-02",{"date":86,"type":32},"2025-06-30",{"date":88,"type":21},"2028-12-30",{"name":38,"class":39},{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":94,"acronym":4,"eligibilityCriteria":95,"healthyVolunteers":11,"sex":48,"minAge":96,"maxAge":4,"enrollmentInfo":97,"targetDuration":4,"studyType":22,"phases":99,"briefSummary":100,"conditions":101,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":109,"locationsCount":40},"100517136","phase-2-clinical-analysis-of-naxitamab-hu3f8-in-the-treatment-of-pediatric-high-risk-or-refractory-relapsed-neuroblastoma-100517136","NCT06013618","Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory\u002F Relapsed Neuroblastoma","Inclusion Criteria:\n\n1)Confirmed diagnosis of high-risk NB 2)1 year of age or above 3)Patient or parent\u002Fguardian must provide written informed consent to participate 4)If patient is sexually active, the patient agrees to use effective contraception 5)Confirmed negative urine pregnancy test for sexually active female of child-bearing potential (post-menarche)\n\nExclusion Criteria:\n\n1. Significant organ toxicity\n2. Known or suspected allergy or hypersensitivity to anti-GD2 antibodies or to GM-CSF or its s components.\n3. Patient is pregnant, planning to become pregnant (while being treated with naxitamab) or is currently breastfeeding\n4. Patient will undergo treatment with another investigational drug, whilst being treated with naxitamab or has received another investigational drug within the 4 weeks prior to commencing treatment with naxitamab\n5. Patient is either eligible and able to participate in or is currently participating in an active interventional Y-mAbs sponsored clinical trial with naxitamab within the indication applied for\n6. Patient is unable to comply with the naxitamab treatment or has a medical condition that would potentially increase the severity of the toxicities experienced from naxitamab treatment at the discretion of the treating physician\n7. Left ventricular ejection fraction of \\\u003C50% by echocardiography OR other clinically relevant cardiac disorders at the discretion of the investigator\n8. Inadequate pulmonary function defined as evidence of dyspnea at rest, exercise intolerance, and\u002For chronic oxygen requirement. In addition, room air pulse oximetry \\\u003C 94% and\u002For abnormal pulmonary function tests if these assessments are clinically indicated\n\n   Applicable for treatment with naxitamab in combination with GM-CSF only:\n9. Patient has active progression of the NB disease\n10. Patient has active NB disease at primary site or soft-tissue metastasis\n11. Patient has known CNS metastases when initiating naxitamab treatment","12 Months",{"count":98,"type":21},120,[54],"This is an prospective study to evaluate the safety and efficacy of naxitamab monotherapy or combined with chemotherapy or combined with chemotherapy and checkpoint inhibitor in the treatment of pediatric high-risk and refractory\u002Frelapsed neuroblastoma in Sun Yat-sen University Cancer Center.",[102],"Neuroblastoma","2025-06-13",{"date":105,"type":32},"2025-06-17",{"date":107,"type":32},"2023-06-19",{"date":67,"type":21},{"name":38,"class":39},{"id":111,"slug":112,"hasResults":11,"nctId":113,"briefTitle":114,"officialTitle":115,"acronym":4,"eligibilityCriteria":116,"healthyVolunteers":11,"sex":48,"minAge":17,"maxAge":117,"enrollmentInfo":118,"targetDuration":4,"studyType":22,"phases":120,"briefSummary":121,"conditions":122,"keywords":125,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":137},"100573716","phase-3-ql1706-pd-1ctla-4-bi-specific-antibody-and-chemoradiotherapy-in-locoregionally-advanced-nasopharyngeal-carcinoma-100573716","NCT06749899","QL1706 (PD-1\u002FCTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.","QL1706 (Iparomlimab and Tuvonralimab Injection,PD-1\u002F CTLA-4 Bi-specific Antibody) Combined With Chemoradiotherapy Versus Chemoradiotherapy Alone in High-Risk Locoregionally Advanced Nasopharyngeal Carcinoma：A Randomized, Controlled, Multicenter Phase III Clinical Study.","Inclusion Criteria\n\n1. Age ≥18 and ≤65 years\n2. Patients with histologically confirmed non-keratinizing nasopharyngeal carcinoma according to WHO criteria.\n3. Tumor staged as T4N1 and T1-4N2-3 (AJCC 9th)\n\n   * Stage II: T1-3N2\n   * Stage III: T1-4N3, T4N1-2\n4. Eastern Cooperative Oncology Group performance score of 0-11.\n5. Adequate marrow function: white blood cell count \\> 4 × 10⁹\u002FLhemoglobin \\>90g\u002FL and platelet count \\>100×10⁹\u002FL\n6. Adequate hepatic and renal function：\n\n   * Total bilirubin ≤ 1.5 × upper limit of normal (ULN)\n   * Alanine Aminotransferase (ALT)\u002FAspartate Aminotransferase (AST) ≤2.5×ULN\n   * Alkaline phosphatase ≤ 2.5 × ULN\n   * clearance rate ≥ 60 ml\u002Fmin\n7. Other laboratory and clinical criteria\n\n   * Normal thyroid function, serum amylase and lipase, pituitary hormone levels, inflammatory markers, cardiac enzyme tests and electrocardiogram (ECG)\n   * For patients aged \\>50 years with a history of smoking, normal pulmonary function test (PFT) results are required\n   * For patients with abnormal ECG findings or a prior history of cardiovascular disease (not meeting any exclusion criteria listed in Item 8), additional assessments including myocardial function evaluation and cardiac ultrasound (echocardiography) must be performed, with results within normal limits\n8. Patients must be informed of the investigational nature of this study and give written informed consent, and be willing and able to comply with the study schedule, including follow-up visits, treatment procedures, laboratory testing, and other protocol-related requirements.\n9. Women of childbearing potential (WOCBP) must be willing to adhere to effective contraception during treatment and for 1 year after the last dose of study drug (e.g., condoms, physician-guided regular use of oral contraceptives).\n\nExclusion Criteria\n\n1. Positive for hepatitis B surface antigen (HBsAg) with hepatitis B virus DNA \\>1×103 copies\u002FmL, positive for anti-hepatitis C virus (HCV) antibody , positive for anti-hepatitis C virus (HCV) antibody\n2. Positive for anti-HIV antibody or diagnosed with acquired immunodeficiency syndrome (AIDS).\n3. Active pulmonary tuberculosis: Patients with a history of active tuberculosis within the past year should be excluded regardless of treatment status. Patients with a history of active pulmonary tuberculosis more than one year prior should also be excluded, unless they received confirmed and regular anti-tuberculosis treatment.\n4. Active, known, or suspected autoimmune diseases, including but not limited to uveitis, colitis, hepatitis, hypophysitis, nephritis, vasculitis, systemic lupus erythematosus, hyperthyroidism, hypothyroidism, and asthma requiring bronchodilators. Type I diabetes, hypothyroidism treated with replacement therapy, and skin disease that doesn't require systemic treatment (e.g., vitiligo, psoriasis, or alopecia) are allowed.\n5. Thymic epithelial tumors (TETs), including thymoma, thymic carcinoma, and thymic neuroendocrine tumors (NETTs).\n6. History of interstitial lung disease or pneumonia requiring oral or intravenous corticosteroids within the past year; use of vancomycin within the past month.\n7. Ongoing chronic systemic corticosteroid therapy (equivalent to or greater than prednisone \\>10mg per day) or any other immunosuppressive therapy. Patients received inhale or topical corticosteroid are allowed.\n8. Uncontrolled cardiac conditions, such as:\n\n   * Heart failure with New York Heart Association (NYHA) classification ≥ Class II;\n   * Unstable angina;\n   * History of myocardial infarction within the past year;\n   * Supraventricular or ventricular arrhythmias requiring treatment or intervention\n9. Pregnant or breastfeeding women (pregnancy testing should be considered for women of childbearing potential with active sexual life)\n10. History or presence of other malignancies, except for adequately treated non-melanoma skin cancer, carcinoma in situ of the cervix, and papillary thyroid carcinoma.\n11. Known hypersensitivity to macromolecule protein products or any component of QL1706.\n12. Active infections requiring systemic treatment within 1 week prior to enrollment.\n13. Administration of live vaccines within 30 days prior to the first dose of epalurilimab-tovorolimab.\n14. History of organ transplantation or hematopoietic stem cell transplantation.\n15. Any other condition assessed by the investigator as potentially compromising patient safety or compliance, such as severe illnesses requiring urgent treatment (including psychiatric disorders), significantly abnormal laboratory values, or other psychological, familial, or social risk factors.","65 Years",{"count":119,"type":21},580,[24],"The trial aimed to compare QL1706 combined with induction chemotherapy plus concurrent chemoradiotherapy (IC+CCRT) versus IC+CCRT alone in High-risk Locoregionally-Advanced Nasopharyngeal Carcinoma (LANPC).",[123,124],"Nasopharyngeal Cancinoma (NPC)","Nasopharyngeal Cancer",[126,127,128],"Immunotherapy","PD-1\u002FCTLA-4 Bi-specific Antibody","Chemoradiotherapy","2025-05-19",{"date":131,"type":32},"2025-05-22",{"date":133,"type":32},"2025-05-04",{"date":135,"type":21},"2030-12-01",{"name":38,"class":39},19,{"id":139,"slug":140,"hasResults":11,"nctId":141,"briefTitle":142,"officialTitle":142,"acronym":4,"eligibilityCriteria":143,"healthyVolunteers":11,"sex":48,"minAge":144,"maxAge":145,"enrollmentInfo":146,"targetDuration":4,"studyType":22,"phases":148,"briefSummary":149,"conditions":150,"keywords":153,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":163},"100580377","phase-1-safety-and-efficacy-of-car-t-cell-therapy-for-relapsedrefractory-neuroblastoma-and-desmoplastic-small-round-cell-tumors-a-single-arm-open-label-trial-100580377","NCT06836505","Safety and Efficacy of CAR-T Cell Therapy for Relapsed\u002Frefractory Neuroblastoma and Desmoplastic Small Round Cell Tumors: a Single-arm, Open-label Trial.","Inclusion Criteria:\n\n1. Patients who are diagnosed as relapsed\u002Frefractory neuroblastoma or relapsed\u002Frefractory desmoplastic small round cell tumors;\n2. Age 1-50 years, any gender;\n3. Agree to participate in the trial and sign a written informed consent form;\n4. Expected survival of ≥12 weeks;\n5. Karnofsky performance status (for patients ≥16 years) or Lansky performance status (for patients \\\u003C16 years) (Appendix 1) must be at least 50;\n6. Good function of major organs:\n\n   1. Liver function: ALT ≤ 5 times the upper limit of normal for the corresponding age, and bilirubin ≤ 2.0 mg\u002FdL, except for patients with Gilbert-Meulengracht syndrome. Patients with Gilbert-Meulengracht syndrome who have bilirubin ≤ 3.0 times the upper limit of normal and direct bilirubin ≤ 1.5 times the upper limit of normal may be included;\n   2. Renal function: Plasma creatinine ≤ 1.5 times the upper limit of normal, or estimated glomerular filtration rate (eGFR) ≥ 60 mL\u002Fmin\u002F1.73m²;\n   3. Pulmonary function: Oxygen saturation ≥ 95% in room air;\n   4. Cardiac function: Left ventricular ejection fraction (LVEF) ≥ 45%;\n7. Patients using the following medications must meet the following conditions:\n\n   Steroids: Steroid treatment doses must be stopped at least 2 weeks before CAR-T infusion. However, physiological replacement doses of steroids are allowed; Immunosuppressants: Any immunosuppressive drugs must be stopped at least 4 weeks before enrollment; Anti-proliferative treatments other than lymphodepleting chemotherapy within two weeks before infusion; CNS disease prophylaxis must be stopped 1 week prior to CAR-T infusion (e.g., intrathecal methotrexate injection);\n8. Patients of childbearing potential (both male and female) must agree to use reliable contraception methods (hormonal or barrier methods or abstinence) with their partner until at least 12 months after CAR-T cell infusion, and until two consecutive flow cytometry or PCR tests show no CAR-T cells in the body;\n9. If the subject cannot provide suitable T cells for CAR-T preparation, T cells from a healthy donor may be collected for preparation.\n\nExclusion Criteria:\n\n* Patients with any of the following items will not be enrolled in this study:\n\n  1. Patients with increased intracranial pressure or altered consciousness;\n  2. Patients who have received radiation therapy within 2 weeks prior to infusion;\n  3. Patients with active hepatitis B (defined as HBV DNA \\> 500 IU\u002FmL) or hepatitis C (HCV RNA positive);\n  4. HIV-positive patients or patients with a positive syphilis test;\n  5. Patients with uncontrolled acute life-threatening bacterial, viral, or fungal infections (e.g., positive blood cultures within ≤72 hours before infusion);\n  6. Patients with unstable angina and\u002For myocardial infarction within 6 months prior to screening;\n  7. Patients with a history of or concurrent malignancies, except for the following conditions:\n\n     1. Basal cell carcinoma or squamous cell carcinoma that has been adequately treated (sufficient wound healing required before study enrollment);\n     2. Carcinoma in situ of the cervix or breast that has been cured, with no signs of recurrence for at least 3 years before the study;\n     3. Primary malignant tumors that have been completely resected and have been in complete remission for ≥5 years;\n  8. Pregnant or breastfeeding female patients;\n  9. Patients with uncontrolled arrhythmias that have not been managed medically;\n  10. Patients who need oral anticoagulation therapy within 1 week before CAR-T cell infusion;\n  11. Patients with active neuroautoimmune or inflammatory diseases (e.g., Guillain-Barré syndrome, amyotrophic lateral sclerosis);\n  12. Other conditions deemed inappropriate for participation in the clinical study by the investigator.\n\nPatients enrolled in the clinical study must meet the inclusion criteria and not meet the exclusion criteria.","1 Year","50 Years",{"count":147,"type":21},10,[53,54],"Title: Safety and efficacy of CAR-T cell therapy for relapsed\u002Frefractory neuroblastoma and desmoplastic small round cell tumors: a single-arm, open-label trial.\n\nThe CART used in this study will be provided by Shanghai YaKe Biotechnology Ltd.\n\nAims:\n\n1. To evaluate the safety and efficacy of GD2\u002FB7H3 CAR-T therapy for relapsed\u002Frefractory neuroblastoma, and observe its pharmacokinetic\u002Fpharmacodynamic characteristics and the survival of CAR-T cells in relapsed\u002Frefractory neuroblastoma patients.\n2. To evaluate the safety and efficacy of GD2\u002FB7H3 CAR-T therapy for relapsed\u002Frefractory desmoplastic small round cell tumor, and observe its pharmacokinetic\u002Fpharmacodynamic characteristics and the survival of CAR-T cells in desmoplastic small round cell tumor patients.\n\nPatients: Relapsed\u002Frefractory neuroblastoma; Relapsed\u002Frefractory desmoplastic small round cell tumor.\n\nCAR-T therapy: Lymphodepletion treatment will be performed within 14 days prior to CAR-T cell infusion: intravenous chemotherapy based on fludarabine 25mg\u002Fm² and cyclophosphamide 500mg\u002Fm² for 1 to 3 days. CAR-T cells will then be infused intravenously, with a dosage of 1.00 to 10.00 × 10⁶\u002Fkg of CAR-positive T cells.\n\nResearch period: CAR-T cell infusion will be followed up for one year, or until adverse events resolve, progression occurs, or the patient transitions to other treatments.\n\nOutcome measures:\n\nIncidence of adverse events related to CAR-T therapy, as well as their intensity and duration; Pharmacokinetic\u002Fpharmacodynamic characteristics of CAR-T in patients and the survival of CAR-T cells.\n\nOverall response rate (ORR) after CAR-T cell infusion, including complete response (CR) and partial response (PR); Overall survival (OS), progression-free survival (PFS), event-free survival (EFS), time to progression (TTP), and duration of response (DOR) after CAR-T cell infusion;",[151,152],"Neuroblastoma (NB)","Desmoplastic Small Round Cell Tumor (DSRCT)",[154],"CART, Neuroblastoma, Desmoplastic Small Round Cell Tumor","2025-02-25",{"date":157,"type":32},"2025-02-26",{"date":159,"type":32},"2024-12-12",{"date":161,"type":21},"2027-12-12",{"name":38,"class":39},3,{"id":165,"slug":166,"hasResults":11,"nctId":167,"briefTitle":168,"officialTitle":169,"acronym":4,"eligibilityCriteria":170,"healthyVolunteers":11,"sex":48,"minAge":4,"maxAge":4,"enrollmentInfo":171,"targetDuration":173,"studyType":174,"phases":4,"briefSummary":175,"conditions":176,"keywords":178,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":183,"startDateStruct":185,"completionDateStruct":187,"leadSponsor":189,"locationsCount":40},"100559211","individualized-tumor-informed-ctdna-analysis-for-monitoring-postoperative-recurrence-in-escc-neocrtec2401-100559211","NCT06561178","Individualized Tumor-Informed CtDNA Analysis for Monitoring Postoperative Recurrence in ESCC (NEOCRTEC2401)","Individualized Tumor-Informed Circulating Tumor DNA (ctDNA) Analysis for Monitoring Postoperative Recurrence Following Neoadjuvant Therapy in Esophageal Squamous Cell Carcinoma (NEOCRTEC2401)","Inclusion Criteria:\n\n1. Operable locally advanced esophageal squamous cell carcinoma;\n2. Have received neoadjuvant chemoradiotherapy ± immunotherapy and have not achieved pCR after R0 resection;\n3. Can tolerate postoperative adjuvant immunotherapy;\n4. Sufficient baseline tumor tissue and blood samples available for NGS testing;\n5. Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1;\n6. Consents to and is capable of complying with the scheduled study visits, treatment plans, laboratory tests, and other study procedures\n7. Expected postoperative survival time of ≥ 6 months.\n\nExclusion Criteria:\n\n1. Concurrent other malignant tumors;\n2. Lack of a detailed histopathological diagnostic report for determining the nature of the lesion;\n3. Severe and\u002For poorly controlled medical conditions that, in the investigator's judgment, could affect participation or interfere with study results;\n4. Any social\u002Fpsychological issues that, in the investigator's judgment, make the patient unsuitable for participation;\n5. Unable to undergo long-term, regular postoperative follow-up at the current medical institution;\n6. Unwilling or unable to comply with the study protocol.",{"count":172,"type":21},50,"5 Years","OBSERVATIONAL","The goal of this observational study or is to explore the correlation between dynamic changes in postoperative circulating tumor DNA (ctDNA) and recurrence risk using a novel, tumor-informed ctDNA detection technique, thus laying the foundation for further promoting ctDNA detection to guide postoperative adjuvant therapy decisions. This study focuses on patients with esophageal squamous cell carcinoma who did not achieve pCR following neoadjuvant therapy combined with surgical resection. The main question it aims to answer is:\n\nIs there a correlation between postoperative ctDNA changes and tumor recurrence?\n\nParticipants will be asked to undergo postoperative ctDNA detection.",[177],"Esophageal Squamous Cell Carcinoma",[179,180,181],"ctDNA","recurrence detection","esophageal squamous cell carcinoma","2024-08-27",{"date":184,"type":32},"2024-08-29",{"date":186,"type":32},"2024-08-26",{"date":188,"type":21},"2028-06-01",{"name":38,"class":39},""]